GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Futura Medical PLC (LSE:FUM) » Definitions » Debt-to-EBITDA

Futura Medical (LSE:FUM) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Futura Medical Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Futura Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.00 Mil. Futura Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.00 Mil. Futura Medical's annualized EBITDA for the quarter that ended in Dec. 2023 was £-9.88 Mil. Futura Medical's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Futura Medical's Debt-to-EBITDA or its related term are showing as below:

LSE:FUM's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.31
* Ranked among companies with meaningful Debt-to-EBITDA only.

Futura Medical Debt-to-EBITDA Historical Data

The historical data trend for Futura Medical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Futura Medical Debt-to-EBITDA Chart

Futura Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Futura Medical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Futura Medical's Debt-to-EBITDA

For the Biotechnology subindustry, Futura Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Futura Medical's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Futura Medical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Futura Medical's Debt-to-EBITDA falls into.



Futura Medical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Futura Medical's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -6.833
=0.00

Futura Medical's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Futura Medical  (LSE:FUM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Futura Medical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Futura Medical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Futura Medical (LSE:FUM) Business Description

Traded in Other Exchanges
Address
40 Occam Road, Surrey Technology Centre, Guildford, Surrey, GBR, GU2 7YG
Futura Medical PLC is a pharmaceutical company based on technology. The company manufactures drugs and is based in the United Kingdom. The company lays primary focus on topically applied pharmaceutical drugs and medical devices which are developed using a efficient and proprietary transdermal delivery technology, DermaSys. DermaSys is a versatile technology that can be customized to suit the specific active compound being used and the therapeutic indication. The company's products are used mainly for the treatment of erectile dysfunction and pain relief.

Futura Medical (LSE:FUM) Headlines

No Headlines